Search Videos and More
News
Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map
Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, childhood cancers carry few genetic mutations.
News
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy
Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
News
mRNA Takes Center Stage in COVID-19 Vaccine and Cancer Research
Having come to fame as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19, messenger RNA — or mRNA — is in many ways the molecule of the moment.
News
Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care
The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
News
Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment
Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive?
Video
Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.
News
Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy
Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.
News
Pediatric Fertility Preservation Program
At Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, we value the importance of fertility and reproductive health as it relates to long-term quality of life. As treatment for childhood cancers and blood disorders have improved, more and more survivors are entering their reproductive years and thinking about starting families of their own. The fertility preservation team will work closely with patients’ primary care team to ensure that a fertility consultation takes place as a part of the patient’s comprehensive work-up.
Video
Bladder Cancer Advances
Dana-Farber's Guru Sonpavde, MD discusses two studies with promising results. One study looks at pre-operative therapy, the other study compares an antibody-drug conjugate to chemotherapy in urothelial carcinoma.
Video
Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research
In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.
News
Expert Panel Issues Recommendations for Addressing Cancer Inequities
New recommendations co-developed by Dana-Farber Cancer Institute call for a significant expansion of the National Cancer Institute (NCI) and NCI-designated Comprehensive Cancer Centers to understand the causes of inequities in cancer care and a commitment to building sustained community partnerships to reduce them.
News
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant
An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.